Future Health | Shatin Li Qian: The opportunity of the ophthalmology market comes from the huge gap between demand and supply side

In the past three years, ophthalmology has been one of the most concerned tracks in the capital market. Especially in the first -level market, the financing cases in the track are more than dozens of cases every year, and the degree of suction can be seen. The industry's consensus is that the domestic ophthalmology market will increase from about 26 billion yuan to 100 billion yuan in the next ten years.

But when the rapidly rising ophthalmology track meets the current capital cold winter, how can startups break through? This issue of "Future Health" focuses on this topic, and invites Li Qian, senior consulting director of Shaliwen Medical Industry, to discuss with Zhang Hao, editor -in -chief of Jingguan.

Li Qian said that the potential of the ophthalmology market exists for a long time. In addition to the rapid growth of the demand side, the opportunity is more from the huge gap between demand and supply side. At present, 1.1 billion people in China and the world are plagued by eye diseases and vision damage, but the current mature drug treatment at this stage is mainly to delay the disease process. Fundamental healing. In fact, there are quite a lot of unsatisfactory needs in the ophthalmidic drug market. This is an opportunity to see many innovative pharmaceutical companies.

Regarding the current cold winter of the capital market, she thinks that she cannot understand one -sidedly, which more reflects that investors are more cautious and calm about the biomedical market. Before, the tumor field was obviously over -fire, and the entire track was too crowded. The market's fieryness and even some chaos, such as everything to raise valuations, and now investors have begun to rethink the track and company.

Back to the ophthalmology track, the influence of capital cold winter still exists, but she thinks it will be better than other fields. The first is because the ophthalmology track is still in the early stage of starting. In traditional sense, it is the most suitable stage of capital to enter; the second to the ophthalmology market does have a huge unconventional demand, and the return on investment is relatively expected.

According to her observation, ophthalmology companies have now begun to show signs of layering. The entire field is currently divided into three types of enterprises. One is mature traditional ophthalmology pharmaceutical companies, such as Xingqi Eye Medicine, Kanghong Pharmaceutical, etc.; The second is ophthalmological innovation pharmaceutical companies during the research and development stage, such as vitamin creatures and cloud biology. Best in, Class "(the best type) and" first in class "products are mainly products; the third is large companies that lay out the ophthalmology track, such as Hengrui Pharmaceutical.

With the development of these three types of enterprises, the domestic ophthalmology market structure may undergo tremendous changes. At present, foreign -funded pharmaceutical companies in the entire market account for more than half of the market share, especially at the hospital. There are only one domestic pharmaceutical company in the top of the first few of the ophthalmology pharmaceutical companies.

"Domestic alternatives" will be a big opportunity. At present, the pipelines of ophthalmic pharmaceutical companies are still in the clinical research and development stage. After three or five years, a number of domestic ophthalmological innovation drugs should be gradually matured, and the original market structure should be gradually broken, and the share of importers is gradually squeezed. Similar development paths have been repeatedly staged in the fields of cardiovascular intervention, and the process of ophthalmological alternatives will last more than ten years.

Moreover, the development of channels has brought more opportunities to ophthalmology companies. Li Qian pointed out that in recent years, the number of domestic private ophthalmic medical institutions has increased, and the penetration rate of ophthalmia diagnosis and treatment has greatly increased, and the drug market will also grow rapidly.

At the same time, ophthalmology has a lot of diseases that are partial consumer attributes, closer to the C end. For such diseases, Internet channels have greater potential outside the traditional pharmaceutical sales channels. The future of Internet channels is not only an important C -end sales position. Li Qian said that the proportion of medicines in the hospital at this stage will exceed 50 %, but the share of the C -end will definitely account for the future.

Author: Yu Shiqi Zhang Hao

- END -